Discover
CCCC
C4 Therapeutics, Inc.
2.78
2 x 2.05
2 x 3.34
bid
ask
+
0.17
6.51%
2 @ 04:00 AM
2.79 +0.01 (0.36%)
| Ytd | 45.55% | |
| 1y | 12.10% |
2.60
day range
2.85
1.69
52 week range
5.17
| Open | 2.64 | Prev Close | 2.61 | Low | 2.60 | High | 2.85 | Mkt Cap | 342.01M |
| Vol | 3.27M | Avg Vol | 2.35M | EPS | -0.91 | P/E | N/A | Forward P/E | -2.37 |
| Beta | 3.07 | Short Ratio | 7.10 | Inst. Own | 91.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 3.51 | 200-d Avg | 3.15 | 1yr Est | 15.00 |
| Income Statement | |||
| Total Revenue | 6.64M | ||
| Revenues (USD) | 6.64M | ||
| Gross Profit | 6.64M | ||
| Operating Expenses | 33.06M | ||
| Research and Development Expense | 24.47M | ||
| Selling, General and Administrative Expense | 8.59M | ||
| Operating Income | -26.42M | ||
| Net Income | -23.63M | ||
| Net Income Common Stock | -23.63M | ||
| Net Income Common Stock (USD) | -23.63M | ||
| Consolidated Income | -23.63M | ||
| Earnings per Basic Share | -0.18 | ||
| Earnings per Basic Share (USD) | -0.18 | ||
| Earnings per Diluted Share | -0.18 | ||
| Earning Before Interest & Taxes (EBIT) | -23.63M | ||
| Earning Before Interest & Taxes (USD) | -23.63M | ||
| Weighted Average Shares | 130.70M | ||
| Weighted Average Shares Diluted | 130.70M | ||
| Balance Sheet | |||
| Cash and Equivalents | 82.05M | ||
| Cash and Equivalents (USD) | 82.05M | ||
| Investments | 221.84M | ||
| Investments Current | 175.05M | ||
| Investments Non-Current | 46.79M | ||
| Trade and Non-Trade Receivables | 1.33M | ||
| Current Assets | 262.90M | ||
| Property, Plant & Equipment Net | 41.79M | ||
| Total Assets | 359.40M | ||
| Debt Current | 6.68M | ||
| Total Debt | 56.86M | ||
| Current Liabilities | 48.25M | ||
| Debt Non-Current | 50.18M | ||
| Total Liabilities | 112.14M | ||
| Accumulated Retained Earnings (Deficit) | -787.46M | ||
| Accumulated Other Comprehensive Income | -444.00K | ||
| Shareholders Equity | 247.27M | ||
| Shareholders Equity (USD) | 247.27M | ||
| Assets Non-Current | 96.50M | ||
| Total Debt (USD) | 56.86M | ||
| Deferred Revenue | 40.38M | ||
| Liabilities Non-Current | 63.89M | ||
| Trade and Non-Trade Payables | 1.12M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.75M | ||
| Net Cash Flow from Financing | 33.73M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 17.34M | ||
| Capital Expenditure | -37.00K | ||
| Issuance (Purchase) of Equity Shares | 33.73M | ||
| Net Cash Flow from Investing | -14.81M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -14.78M | ||
| Net Cash Flow from Operations | -1.57M | ||
| Share Based Compensation | 3.04M | ||